Adaptive Biotechnologies Corporation · Q4 2022 earnings

Briefing

Adaptive Biotechnologies reported a 46% increase in revenue, driven by MRD and Immune Medicine business areas.

Adaptive Biotechnologies reported a revenue of $55.2 million for Q4 2022, a 46% increase compared to the previous year. The company's net loss was $40.2 million, and adjusted EBITDA was a loss of $19.6 million. They ended the year with $498.2 million in cash, cash equivalents and marketable securities.

• Revenue of $55.2 million, representing a 46% increase year-over-year.
• clonoSEQ test volume increased 54% to 10,526 tests delivered.
• Launched clonoSEQ to assess MRD in patients with diffuse large B-cell lymphoma (DLBCL) with Medicare coverage.
• Ended the year with $498.2 million in cash, cash equivalents and marketable securities.

Headline financials

Revenue & EPS history

Adaptive Biotechnologies expects full year 2023 revenue to be in the range of $205 million to $215 million. We expect operating expenses, including cost of revenue, to be below full year 2022 operating expenses of $385.5 million.